58 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Sep 2032. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Sep 2032
Next term end
3
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Feb 2039 · High confidence
Also notable
Ends Feb 2039 · High confidence
Also notable
Ends Mar 2043 · Medium confidence
Managing Insulin Administration
US 11,062,798
Cited by 57 later US patents, top 5% of utility patents granted in 2021 in our data. Protection runs to 2039.
Advising Diabetes Medications
US 11,568,974
A family of 5 related applications built on the 2023 grant. Protection runs to 2039.
Advising Diabetes Treatments
US 12,688,921
Granted 2026. Too new for citation comparison; protection runs to 2043.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 20, 2026The maintenance fee for Subcutaneous Outpatient Management (US 11,678,800) comes due Dec 20, 2026. Unpaid by Jun 21, 2027, it lapses early.
- 1 fee due Jan 4, 2027The maintenance fee for A Method and Dosing Controller for Subcutaneous Outpatient Management (US 11,694,785) comes due Jan 4, 2027. Unpaid by Jul 6, 2027, it lapses early.
- 3 fees due Feb 13 to 22, 2027 · next Feb 13
- 2 fees due Mar 3 to 10, 2027 · next Mar 3
- 5 fees due Apr 10 to 30, 2027 · next Apr 10
- 3 fees due Jul 2 to 14, 2027 · next Jul 2
- 1 fee due Aug 20, 2027The maintenance fee for Advising Diabetes Medications (US 11,908,561) comes due Aug 20, 2027. Unpaid by Feb 22, 2028, it lapses early.
- 1 fee due Oct 21, 2027The maintenance fee for Means and Method for Improved Glycemic Control for Diabetic Patients (US 10,629,294) comes due Oct 21, 2027. Unpaid by Apr 21, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 16, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| System and Method for Optimizing Insulin Dosages for Diabetic Subjects | 52 in force | to Feb 2039 |
| Advising Diabetes Medications | 4 in force | to Feb 2039 |
| Advising Diabetes Treatments | 2 in force | to Mar 2043 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,483,619 | Means and Method For Improved Glycemic Control For Diabetic Patients In force · High confidence | In force | High confidence | |
| US 9,773,096 | Means and Method For Improved Glycemic Control For Diabetic Patients In force · Medium confidence | In force | Medium confidence | |
| US 9,811,638 | Means and Method For Improved Glycemic Control For Diabetic Patients In force · Medium confidence | In force | Medium confidence | |
| US 9,965,596 | Means and Method for Improved Glycemic Control for Diabetic Patients In force · Medium confidence | In force | Medium confidence | |
| US 10,102,922 | Means and Method For Improved Glycemic Control For Diabetic Patients In force · Medium confidence | In force | Medium confidence | |
| US 10,410,740 | Means and Method for Improved Glycemic Control for Diabetic Patients In force · Medium confidence | In force | Medium confidence | |
| US 10,629,294 | Means and Method for Improved Glycemic Control for Diabetic Patients In force · Medium confidence | In force | Medium confidence | |
| US 11,131,643 | Method and System for Optimizing Insulin Dosages for Diabetic Subjects In force · High confidence | In force | High confidence | |
| US 11,733,196 | System and Method for Optimizing Insulin Dosages for Diabetic Subjects In force · High confidence | In force | High confidence | |
| US 9,171,343 | Means and Method for Improved Glycemic Control for Diabetic Patients In force · High confidence | In force | High confidence |
Also on record, not counted in the 58: 1 patent ended · 6 applications pending · 5 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.